Luveris® (lutropin alfa) for Ovulation Support and IVF Protocols

What Luveris® Is and How It Works

Luveris (lutropin alfa) is recombinant human luteinizing hormone (LH). It is used with follicle-stimulating hormone (FSH) to support follicular development in women with severe LH and FSH deficiency. It is supplied as a powder for subcutaneous injection after reconstitution. Many patients compare Luveris price options, especially when paying luveris without insurance.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing.

We work with licensed, vetted international partner pharmacies so you can access authentic brand medications from a broad selection at affordable pricing.

LH supports theca cell function and ovarian steroid production. In treatment cycles, Luveris 75 IU is typically given once daily with an FSH product. Dose adjustments focus on the FSH component based on ovarian response. A trigger dose of human chorionic gonadotropin (hCG) may be used when follicles mature. These protocols are tailored by fertility specialists to goals such as ovulation induction or assisted reproduction.

If you are exploring causes and treatment paths, our pages on Infertility and Ovarian Stimulation offer helpful overviews.

Dosage and Usage

• Typical initiation: Luveris 75 IU subcutaneously once daily with an FSH product. The Luveris dose usually remains 75 IU throughout the stimulation phase.
• Titration: Adjust the FSH dose according to estradiol levels and ultrasound findings. The prescribing clinician sets monitoring schedules and cycle length.
• Reconstitution: Use the provided solvent. Aim the diluent into the vial wall, swirl gently to dissolve, and avoid vigorous shaking.
• Inspection: Use only if the solution is clear, particle-free, and colorless. Do not use if the vial or solution looks damaged.
• Injection sites: Abdomen or thigh subcutaneous tissue. Rotate sites to reduce skin irritation.
• Timing: Inject at the same time each day during the stimulation phase unless instructed otherwise.
• Missed dose: Contact the clinic for guidance. Do not double the next dose without medical advice.
• Sharps disposal: Use an approved sharps container. Follow local regulations for disposal.

• Storage before mixing: Refrigerate vials at 2–8 °C (36–46 °F). Do not freeze. Keep in the original carton to protect from light.
• After mixing: Use immediately. Do not store reconstituted solution. Discard any unused portion.
• Travel: Use an insulated bag with frozen gel packs. Keep vials close to the gel packs, not directly touching ice to prevent freezing.
• Handling: Avoid excessive heat or prolonged room-temperature exposure. Keep vials secure and upright.
• Shipping: Your order ships with prompt, express, cold-chain shipping to maintain temperature control.

Benefits and Savings

Luveris helps provide the LH activity needed for adequate estradiol production and follicular maturation. When combined with FSH, it can improve response in women with very low endogenous LH. It uses a small-volume subcutaneous injection, and the 75 IU vial format supports cycle-by-cycle dosing plans.

Ordering from Canada can reduce costs substantially. Many patients save 60–80% compared with typical US pharmacy prices. This can ease luveris out of pocket expenses and reduce the overall Luveris cost for a treatment cycle. Savings are helpful if paying luveris without insurance or using a health savings account.

You can buy Luveris online through our secure checkout. Reorder reminders help you time refills for upcoming cycles. Multi-month supplies, when appropriate for your plan, can lower the per-month price, and occasional bulk promotions may further reduce the Luveris 75 IU price. For seasonal offers, see our luveris coupon page.

Side Effects and Safety

• Injection site reactions: pain, redness, bruising, or swelling
• Headache or fatigue
• Abdominal discomfort or bloating
• Nausea
• Breast tenderness
• Ovarian cysts or enlargement
• Mood changes
• Upper respiratory symptoms

Serious risks are uncommon but include ovarian hyperstimulation syndrome (OHSS), multiple pregnancy, ovarian torsion, blood clots, and allergic reactions. Seek urgent care for severe pelvic pain, rapid weight gain, shortness of breath, or signs of anaphylaxis. Patients with uncontrolled thyroid or adrenal disorders, hormone-sensitive tumors, primary ovarian failure, or unexplained uterine bleeding generally should not receive gonadotropins.

Onset Time

Follicular response typically appears within the same stimulation cycle as dosing begins. Estradiol levels may start rising within several days. Ultrasound monitoring often shows follicle growth over 7–14 days as FSH dosing is adjusted. When follicles reach target size, an hCG trigger may be scheduled.

Ovulation induction cycles often complete within two to three weeks, depending on response and clinic protocols. In assisted reproduction, timing aligns with retrieval windows set by the care team. Clinical pregnancy rates vary by age, diagnosis, oocyte quality, and the broader protocol used alongside Luveris.

Compare With Alternatives

Gonal-f (follitropin alfa) and other recombinant FSH products supply FSH only. In women with severe LH and FSH deficiency, an LH source may be needed to support optimal estradiol production. Luveris provides LH specifically and is paired with FSH for a tailored response.

Menopur (menotropins, hMG) contains both FSH and LH activity derived from urinary sources. Some clinicians prefer purified or recombinant mixtures, while others use separate recombinant LH plus FSH for fine-tuning. Protocol choice depends on your lab’s experience, monitoring results, and treatment goals.

hCG products, such as choriogonadotropin alfa, are generally used as a trigger rather than for ongoing LH support. They mimic the LH surge to time ovulation or oocyte retrieval. Your clinic will select between recombinant and urinary-derived agents based on response, availability, and cost considerations.

Combination Therapy

• Luveris with recombinant FSH (e.g., follitropin alfa or beta) for stimulation in LH/FSH deficiency
• Luveris with hMG in select protocols when extra LH activity is needed
• GnRH antagonist or agonist regimens used alongside to control premature luteinization
• hCG trigger scheduled once follicles reach target size on ultrasound
• FSH dose reductions considered to limit OHSS risk if estradiol rises rapidly

Patient Suitability and Cost-Saving Tips

Luveris is intended for women with severe LH and FSH deficiency who need LH support in addition to FSH. It is not for primary ovarian failure or pregnancy. It is also not indicated in men. Contraindications include tumors of the pituitary or hypothalamus, hormone-sensitive cancers, ovarian enlargement not due to polycystic ovary syndrome, and unexplained uterine bleeding.

Patients with polycystic ovary syndrome may require careful monitoring during stimulation to reduce OHSS risk. Those with uncontrolled thyroid or adrenal disease should have these conditions managed before starting gonadotropins. Always follow the individualized protocol set by your fertility clinic.

To manage Luveris injection price concerns, consider planning purchases per cycle and asking about multi-month options if your protocol is stable. Bulk promotions can reduce the average Luveris 75 cost. Reorder reminders help prevent last-minute rush orders. These steps can be helpful for those who are luveris uninsured or paying luveris cash pay.

Authoritative Sources

EMD Serono Canada: Company site

Health Canada Drug Product Database: Luveris (lutropin alfa)

European Medicines Agency: Luveris EPAR and product information

Order Luveris® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This content is educational and does not replace advice from your healthcare professional. Always follow your prescriber’s instructions and your clinic’s guidance.